CA
TSHA icon

Clearstead Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Clearstead Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-690
Closed -$2.26K – 3247
2025
Q3 		$2.26K Hold
690
– – ﹤0.01% 2414
2025
Q2 		$1.59K Buy
+690
New +$1.5K ﹤0.01% 2372

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clearstead Advisors's TSHA Position: Q4 2025 in Review

Clearstead Advisors sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 690 shares — an estimated $2.26K sold.

Clearstead Advisors first reported a position in TSHA in Q2 2025 and held it in 2 quarters. The position peaked at $2.26K in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Clearstead Advisors reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 690 Taysha Gene Therapies shares in Q4 2025, an estimated $2.26K.
  • Clearstead Advisors first reported a position in Taysha Gene Therapies in Q2 2025 and held it in 2 quarters.
  • Clearstead Advisors's Taysha Gene Therapies position peaked at $2.26K in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.